OncLive TV

Dr. Moran on Techniques to Decrease Toxicities With Radiation in Breast Cancer

September 28th 2016

Meena Savur Moran, MD, radiation oncologist, professor, Therapeutic Radiology, director, Breast Cancer Radiotherapy Program, Yale Cancer Center, discusses some of the techniques that oncologists can use to decrease the toxicities associated with radiation therapy when treating patients with breast cancer.

Next-Generation Sequencing Analysis of Circulating Tumor DNA

September 26th 2016

Oliver Zill, data scientist, Guardant Health, discusses the somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA.

Dr. Mehnert on Promising Biomarkers for Immunotherapy

September 26th 2016

Janice Mehnert, MD, medical oncologist, director, Phase I and Developmental Therapeutics Program, Rutgers Cancer Institute of New Jersey, discussing promising biomarkers for patients to receive immunotherapy across tumor types.

Dr. Wakelee on BIRCH Trial for Atezolizumab in Patients With NSCLC

September 24th 2016

Heather A. Wakelee, MD, associate professor of Medicine (Oncology), Stanford University Medical Center, regent, International Association for the Study of Lung Cancer (IASLC) discusses updated efficacy findings from the BIRCH trial, which was a phase II study of atezolizumab (Tecentriq) for patients with PD-L1–selected advanced non–small cell lung cancer (NSCLC). Wakelee discussed these findings during an interview at the 2016 IASLC Multidisciplinary Symposium on Thoracic Oncology.

Dr. Hirsch on Value of PD-L1 Testing in Patients With Lung Cancer

September 23rd 2016

Fred R. Hirsch, MD, PhD, professor of Medicine, University of Colorado Denver, CEO, the International Association for the Study of Lung Cancer (IASLC), discusses the value of PD-L1 assays for patients with non–small cell lung cancer. Hirsch shared his during an interview at the 2016 IASLC Multidisciplinary Symposium on Thoracic Oncology.

Dr. Brigid Killelea on Nipple-Sparing Mastectomy for Breast Cancer

September 23rd 2016

Brigid Killelea, MD, MPH, FACS, associate professor of surgery (oncology), Yale Cancer Center, discusses the potential of nipple-sparing mastectomy for women who undergo surgery for breast cancer.

Dr. Harvey I. Pass on Personalized Surgical Approaches in Lung Cancer

September 23rd 2016

Harvey I. Pass, MD, director, Thoracic Surgery, Thoracic Oncology, NYU Langone Medical Center, discusses what it means to take a personalized approach to surgery in lung cancer.

Dr. Anees B. Chagpar on the Hottest Topics in Breast Cancer Management

September 23rd 2016

Anees B. Chagpar, MD, associate professor of Surgery (Oncology), director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven, Yale Cancer Center, explains some of the most discussed topics in breast cancer. Chagpar was recently the chair at the State of the Science Summit on Breast Cancer held Sept. 15.

Dr. Stacy Loeb on Considerations for Screening in Prostate Cancer

September 23rd 2016

, assistant professor of urology and population health at New York University (NYU) Langone Medical Center, discusses screening determinations for prostate cancer.

Dr. Gandara on How Lung-MAP Trial is Optimal for Patient Care

September 23rd 2016

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer (IASLC), discusses the Lung Master Protocol (Lung-MAP) Trial and how it is an example of a rational clinical design that will impact patient care. Gandara shared this insight during an interview at the 2016 IASLC Multidisciplinary Symposium on Thoracic Oncology.

Dr. David L. Rimm on Alternatives to PD-L1 to Predict Immunotherapy Response in Lung Cancer

September 22nd 2016

Dr. Matthew Yurgelun on Pathogenic Mutations in CRC

September 22nd 2016

Matthew B. Yurgelun, MD, Targeted Oncology, Yurgelun, Instructor in Medicine, Harvard Medical School, discusses a recent study which uncovered BRCA1 and BRCA2 mutations as possible risk markers for colorectal cancer.

Dr. Saenger on Ongoing Research in Melanoma

September 21st 2016

Yvonne Saenger, MD, director of Melanoma Immunotherapy at Columbia University Medical Center, discusses ongoing research related to immunotherapy in the field of melanoma. Sanger shared this insight during an interview with OncLive during the recent Society for Immunotherapy of Cancer Cancer Immunotherapy 101 meeting in New York City.

Dr. Harigopal on Advances With Breast Cancer Pathology

September 21st 2016

Malini Harigopal, MD, associate professor of Pathology, interim director of Breast Pathology, Yale School of Medicine, Yale Cancer Center, discusses the advancements in the pathology of breast cancer.

Dr. Antoni Ribas on the Search for Immunotherapy Biomarkers in Melanoma

September 21st 2016

Dr. Sanft on HER2-Positive Breast Cancer

September 21st 2016

Tara Sanft, MD, assistant professor of medicine, medical director of adult survivorship for the Yale Cancer Center Survivorship Clinic, discuses advancements in HER2-positive breast cancer.

Dr. Jett on Debates on Molecular Testing for Lung Cancer

September 21st 2016

James R. Jett, MD, professor of Medicine Emeritus, National Jewish Health, discusses the most frequent debates surrounding molecular testing for patients with lung cancer.

Dr. Hofstatter on Identifying High-Risk Patients in Breast Cancer

September 21st 2016

Erin Wysong Hofstatter, MD, associate professor, co-director, Cancer Genetics and Prevention Program, Yale Cancer Center, discusses the important factors for identifying potentially high-risk patients in breast cancer.

Dr. Burtness on Ongoing Trials of Immunotherapy in Head and Neck Cancer

September 21st 2016

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses some of the ongoing trials currently examining the use of immunotherapy to treat patients with head and neck cancer.

Dr. Paty on High-Risk Period for Rectal Tumor Regrowth

September 21st 2016

Philip B. Paty, MD, surgeon, Memorial Sloan Kettering Cancer Center, discusses the high-risk period for rectal tumor regrowth in patients.